Reflecting on Eisai’s Alzheimer’s disease development journey—from Aricept’s U.S. launch in 1997 to Leqembi nearly a quarter century later—the company’s CEO Haruo Na...

Right after an industry survey suggested that switching away from Chinese CDMOs could take biopharma companies up to eight years, lawmakers have adjusted the BIOSECU...

Just about two months into his CEO job at Emergent BioSolutions, Joseph Papa has laid out his turnaround plan for the CDMO-turned-biopharma company. And it involves ...

Following the lead of Eli Lilly, Pfizer will establish a direct-to-consumer service, selling some of its medicines online and avoiding industry middlemen. The compan...

Amid a U.S. biosecurity crackdown targeting certain Chinese manufacturers and contract research organizations, production specialist WuXi Biologics has quietly exite...

Japan’s Ono Pharmaceutical is picking up Deciphera Pharmaceuticals for $2.4 billion, a price tag that brings both the approved cancer drug Qinlock and another candid...

After proving the merits of its drug delivery platform last year with the approval of Teva’s long-acting schizophrenia drug Uzedy, France’s Medincell has hooked anot...

As COVID-19 moves into an endemic phase, though rates of coronavirus infections and hospitalizations continue to fall, cases of long COVID appear to be slowly tickin...

GlobalData has put out a forecast that shows how GLP-1 drugs could rapidly redefine what big looks like in drug sales. The analysts expect Mounjaro to bring in as mu...

Mere weeks after earning the FDA’s signoff on new drug Winrevair to treat pulmonary arterial hypertension (PAH), Merck has kicked off an educational campaign around ...